Polish media outlet Property News has reported that international tobacco giant Philip Morris International Inc (PMI) has announced a new investment plan in Poland worth over 1 billion zloty (approximately $231 million).
PMI Poland has announced a new investment plan worth over 1 billion zlotys. This investment will be used towards the production of the latest IQOS ILUMA heated tobacco pods at their factory in Krakow. The investment is expected to generate a considerable number of job opportunities, benefiting the residents of Krakow and its surrounding areas.
Michal Mierzejewski, the President of PMI's Northern Europe and Eastern Europe region, expressed, "Poland has long held a crucial position in our strategic plans."
According to Mirochevski, PMI has invested 25.5 billion zloty (approximately 5.8 billion US dollars) in Poland since 1996, for the continuous renovation of factories in Krakow and the upgrade of the Krakow research and development center.
PMI has announced that further investment details will be disclosed in the coming months.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
